Melperon Neuraxpharm (Melperone Hydrochloride)

Melperone is a typical antipsychotic that acts on dopaminergic pathways to treat several psychotic conditions.

• Schizophrenia: reduction of positive symptoms such as delusions, hallucinations, and disorganized thinking.
• Acute psychotic episodes: stabilization of mood and perception disturbances.
• Chronic psychotic disorders: maintenance therapy to prevent relapse and improve functional outcomes.

• Melperone exerts its antipsychotic effect primarily by antagonizing dopamine D2 receptors in the mesolimbic and mesocortical pathways, thereby decreasing dopaminergic neurotransmission that underlies psychotic symptoms. It may also exhibit moderate antagonism at serotonin 5‑HT2 receptors, contributing to its overall clinical profile.

Adverse reactions to melperone vary in frequency and severity.

Common Side Effects

• Sedation: feeling unusually drowsy or sleepy.
• Orthostatic hypotension: dizziness or light‑headedness upon standing.
• Dry mouth: reduced salivation leading to discomfort.
• Constipation: decreased bowel motility.
• Weight gain: increase in body weight over time.
• Extrapyramidal symptoms: mild tremor or muscle stiffness.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening fever, rigidity, and autonomic instability.
• Tardive dyskinesia: persistent involuntary movements, often of the face.
• Agranulocytosis: severe reduction in white blood cells, increasing infection risk.
• Seizures: occurrence of convulsive episodes.
• Myocarditis: inflammation of the heart muscle.
• Severe hypotension: marked drop in blood pressure causing fainting.

When prescribing melperone, clinicians should observe several safety measures.

• Monitor extrapyramidal symptoms: assess for tremor, rigidity, or abnormal movements.
• Assess cardiovascular status: watch for orthostatic hypotension and arrhythmias.
• Evaluate metabolic parameters: track weight, glucose, and lipid levels regularly.
• Avoid abrupt discontinuation: taper the dose to reduce withdrawal or relapse risk.
• Use caution in elderly patients with dementia: increased sensitivity to sedation and falls.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Melperone may interact with other medicines, requiring attention to the nature of the interaction.

Major Interactions (Avoid)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase melperone plasma levels.
• Other dopamine antagonists (e.g., haloperidol): additive risk of extrapyramidal symptoms.
• QT‑prolonging agents (e.g., quinidine, sotalol): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation.
• Anticholinergic drugs (e.g., benztropine): may mask extrapyramidal signs.
• Lithium: potential for neurotoxicity; monitor serum lithium levels.